<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317915</url>
  </required_header>
  <id_info>
    <org_study_id>EFC2481</org_study_id>
    <nct_id>NCT00317915</nct_id>
  </id_info>
  <brief_title>Irbesartan in Type 2 Diabetes</brief_title>
  <official_title>The Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <brief_summary>
    <textblock>
      The aim of this multicenter, doubleblind, randomized study was to investigate the
      renoprotective effect of irbesartan treatment in patients with type 2 diabetes and
      microalbuminuria (a precursor of diabetic kidney disease). 590 patients were randomized to a
      median 24 months of treatment with 300 mg irbesartan once daily, 150 mg irbesartan once daily
      or placebo. Time to development of overt nephropathy, defined by persistent proteinuria, was
      the primary outcome measure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of overt nephropathy</measure>
  </primary_outcome>
  <condition>Type 2 Diabetes</condition>
  <condition>Microalbuminuria</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan treatment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Type 2 diabetes. Hypertension. Persistent microalbuminuria. Serum creatinine concentration
        of no more than 1.5 mg per deciliter (133 µmol per liter) for men and no more than 1.1 mg
        per deciliter (97 µmol per liter) for women. -

        Exclusion Criteria:

        Nondiabetic kidney disease. Cancer. Life-threatening disease with death expected to occur
        within two years. Indication for angiotensin-converting– enzyme (ACE) inhibitors or
        angiotensin-II–receptor antagonists. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Henrik Parving, Prof. DMsc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <verification_date>April 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>April 24, 2006</last_update_submitted>
  <last_update_submitted_qc>April 24, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

